Clinical trials: Eyes With Retinal Diseases
Macular Degeneration
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal…
- Trial name
- NCT00061594
- Testing
- rhuFab V2 (ranibizumab)
- Where
- 82 sites in United States, Australia and 4 more
- Volunteers
- 426 people
- Sponsor
- Genentech, Inc.
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy…
- Trial name
- CHROMA (NCT02247479)
- Testing
- Lampalizumab
- Where
- 145 sites in United States, Argentina and 17 more
- Volunteers
- 906 people
- Sponsor
- Hoffmann-La Roche
Neovascular (Wet) Age-related Macular Degeneration
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled.
- Trial name
- NCT05439629
- Testing
- BAT5906 injection, Lucentis
- Where
- 48 sites in China
- Volunteers
- 488 people
- Sponsor
- Bio-Thera Solutions
Age Related Macular Degeneration
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.
- Trial name
- NCT00446654
- Testing
- CGC-11047
- Where
- 8 sites in United States, Mexico and 1 more
- Volunteers
- 43 people
- Sponsor
- Progen Pharmaceuticals
Active Noninfectious Uveitis Affecting the Posterior Segment
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
- Trial name
- TITAN (NCT07218770)
- Testing
- REGN7041
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.